Omnicell (NASDAQ:OMCL) Upgraded by Wall Street Zen to Strong-Buy Rating

Key Points

• Omnicell was upgraded by Wall Street Zen from “buy” to “strong-buy,” adding to a generally bullish analyst backdrop. The stock now has a consensus “Buy” rating and a consensus price target of $59.86.
• Recent earnings beat expectations with Q1 EPS of $0.55 versus $0.33 expected, and revenue of $309.88 million topping estimates. Revenue also rose 14.9% year over year.
• Institutional ownership remains heavy, with hedge funds and asset managers owning 97.7% of the stock. Several major firms increased their positions recently, while an Omnicell executive also sold shares in March.

Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued on Sunday.

A number of other research analysts have also commented on OMCL. Wells Fargo & Company upped their target price on Omnicell from $52.00 to $55.00 and gave the company an "overweight" rating in a research note on Thursday, April 23rd. Benchmark reissued a "buy" rating on shares of Omnicell in a report on Friday, March 13th. Craig Hallum restated a "buy" rating and issued a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Zacks Research raised shares of Omnicell from a "hold" rating to a "strong-buy" rating in a report on Friday, May 1st. Finally, Weiss Ratings upgraded shares of Omnicell from a "sell (d)" rating to a "hold (c-)" rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $59.86.

Omnicell Stock Up 1.1%

OMCL stock opened at $43.82 on Friday. Omnicell has a twelve month low of $25.44 and a twelve month high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.99 billion, a PE ratio of 99.59, a price-to-earnings-growth ratio of 1.10 and a beta of 0.96. The business's 50-day simple moving average is $37.38 and its 200 day simple moving average is $39.87.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm had revenue of $309.88 million during the quarter, compared to analysts' expectations of $304.02 million. During the same quarter in the prior year, the firm posted $0.26 EPS. The company's revenue for the quarter was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, research analysts anticipate that Omnicell will post 1.34 earnings per share for the current year.

Insider Activity at Omnicell

In related news, EVP Corey J. Manley sold 7,405 shares of the business's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the sale, the executive vice president owned 96,717 shares of the company's stock, valued at $3,355,112.73. The trade was a 7.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.92% of the stock is owned by company insiders.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently made changes to their positions in OMCL. Dimensional Fund Advisors LP increased its position in shares of Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company's stock worth $81,791,000 after purchasing an additional 137,834 shares in the last quarter. Wellington Management Group LLP grew its stake in Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company's stock worth $94,014,000 after buying an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC increased its holdings in shares of Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company's stock worth $50,225,000 after buying an additional 62,733 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company's stock worth $47,095,000 after buying an additional 27,497 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Omnicell by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company's stock valued at $51,088,000 after acquiring an additional 11,424 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.